Physician profile
Nelson E Lezcano
NPI 1578874483
$3,938.79
in general payments reported to CMS, 2019-2025
15 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $608 · 2021: $1,168 · 2022: $245 · 2023: $161 · 2024: $132 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $967.99 | 2020-2025 | |
| Amgen INC. | $591.21 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $442.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $316.01 | 2019 | |
| Inari Medical, INC. | $312.86 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $245.73 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.28 | 2019-2021 | |
| Janssen Biotech, INC. | $147.84 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.87 | 2021 | |
| Daiichi Sankyo INC. | $123.84 | 2021 | |
| Glaxosmithkline, LLC. | $121.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.37 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $115.49 | 2019 | |
| Insmed, INC. | $94.98 | 2019 | |
| Pfizer INC. | $26.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Lezcano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.